Novo's weight loss drug approved by US cardiologists Novo Nordisks Wegovy and Eli Lillys Zepbound are mentioned in new guidelines from US cardiologists as drugs to consider for preventing cardiovascular disease
Semaglutide Semaglutide is a long-acting, injectable GLP-1 agonist that can be used as a diabetes treatment
Oral versions of semaglutide are in development and could change the market further when they arrive, removing the barrier of weekly self-injection
If you are losing weight consistently, tolerating the dose well, and feeling good, 8 mg may be where you stay
The pill is easier to make, so it could be more accessible than the injectables, which were often in short supply
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer